Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Donniebrasco57on Jan 03, 2020 10:41am
31 Views
Post# 30514986

RE:RE:Report the troll for Libel / Defamation of Character

RE:RE:Report the troll for Libel / Defamation of Character
HyperionPrime wrote:
HyperionPrime wrote: Report the troll for Libel / Defamation of Character, Market Manipulation, Short and Distort.
 
There is a reason this person posts negative comments on this board 24/7 with a new account every day. It's $$$$$$$$$$$. It desperately wants to scare away investors and make this company fail.

Defamation of character
 happens when something untrue and damaging is presented as a fact to someone else.
 
Libel is a type of defamation. Libel is an untrue defamatory statement that is made in writing. It could be in a blog comment or spoken in a speech or said on television.

Manipulation is intentional conduct designed to deceive investors by controlling or artificially affecting the market for a security. Manipulation can involve a number of techniques to affect the supply of, or demand for, a stock. They include: spreading false or misleading information about a company; improperly limiting the number of publicly-available shares; or rigging quotes, prices or trades to create a false or deceptive picture of the demand for a security. Those who engage in manipulation are subject to various civil and criminal sanctions.

You can report these unlawful statements and acts against Robert Farrell and Kalytera Therapeutics with screenshots to:

Securities and Exchange Commission

Kalytera Therapeutics

Do not reply to the troll directly. 
Do not post under the troll's topic.
It wants it's negative headlines at the top of the board. 




Bullboard Posts